ClinicalTrials.gg
RecruitingNCT06617208PIONEERUpdated Oct 5, 2026

Pilot IntraOperative Neuronal Electrophysiology in Tumor rElatEd suRgery

An interventional study of Neuropixel probe recording in Glioma, Glioblastoma (GBM) and Brain Tumor-Glioma, sponsored by Erasmus Medical Center. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Primary conditionGlioblastomaRegistry: GliomaReclassifiedWhy we changed it
Registry
Glioma — the first condition term the registry derived for this study.
ClinicalTrials.gg
Glioblastoma
Why
  1. The study's listed conditions name Glioblastoma, a narrower term within Glioma.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Erasmus Medical Center · Not applicable, Interventional, and Device feasibility

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.
Updated Oct 5, 2026Now RecruitingFirst site in Netherlands+8 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 92 studies in Glioblastoma with a site in Netherlands — 24 open to participants now, 33 under way, 5 of them phase 3. Glioblastoma · Netherlands.

Planned enrollment
59th of 77
20 · median 76
Started
2026
with 1 other
No phase
15 of 92
7 open now
Primary completion
2030-01
later than 32 of 32 live
Registered
87th of 92
by date
Lead sponsor
8 of 92
Erasmus Medical Center

Among the 92 studies in Glioblastoma with a site in Netherlands, this one is the 59th largest by planned enrollment of the 77 interventional ones that give a count, is one of 2 that started in 2026, is one of 15 with no phase, reaches primary completion later than 32 of the 32 other live ones, and was the 87th registered.

Glioblastoma

2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

24 of the 92 studies in Glioblastoma with a site in Netherlands are open now. Recruiting first, the newest first:

18 more — sign in →

All 24 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 339 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 92 studies in Glioblastoma with a site in Netherlands, or all of them as a file.
02

Study summary

INTRODUCTION AND RATIONALE

Aggressive brain tumors like glioma have the ability to infiltrate the surrounding healthy brain tissue, disrupting normal neuronal activities and leading to impaired motor and cognitive functions, as well as causing epilepsy. This malignant brain tumor is considered one of the most challenging cancers to treat, with a median survival of 12 to 15 months. Recent findings on direct neuron-tumor interactions indicate that abnormal brain activity in the regions surrounding brain tumours may contribute to develop epilepsy and accelerating tumor growth. Tumors tend to 'fuel' themselves with neurotransmitters released during its 'daily' neuronal firing. Hyperactive neurons in the peritumoral cortex can form excitatory electrochemical synapses with surrounding tumor cells, creating direct communication pathways within the peritumoral microenvironment, which aids in the progression and proliferation of tumor cells via direct and paracrine signalling pathways. However, the specific features of this abnormal brain activity in the peritumoral cortex have not been fully clarified and information on the pathological changes of neuronal activity in glioma patients is largely lacking. To advance more effective treatment strategies, it is crucial to better understand the complex interactions between the tumor and the brain.

This is especially important for our group of patients of which many perceive diminished quality of life because of epilepsy, cognitive functioning and language problems after tumor surgery. Furthermore, we lack thorough understanding of what tumor resection does to the original hyperactive peritumoral cortex and if resecting this is beneficial for improving postoperative outcome both for epilepsy as well as regarding survival. Therefore, identifying the hyperactive peritumoral cortex and directly addressing its impacts on the brain function and long-term surgical outcome could be a promising novel therapeutic strategy for treating glioma patients.

STUDY AIM

Our measurement focuses on capturing neuronal activity at single-neuron resolution in the peritumoral cortex of glioma patients using cortical depth electrodes. It is well-established that gliomas can remodel the surrounding brain tissue, leading to abnormal neuronal hyperactivity, which contributes to tumor progression and epilepsy. However, the specific neuronal patterns and underlying mechanisms of these changes are not yet fully understood. Our study will aim to collect detailed single-neuron recordings in this context, enabling us to map the precise neurophysiological disruptions caused by gliomas. On the long term, our research could lay the groundwork in identifying novel therapeutic approaches by providing critical in-sights into how gliomas alter brain function.

Read the detailed description

In this study, patients with a brain tumour who undergo (awake) surgical resection as part of standard clinical care will be included. All patients who undergo such a procedure at Erasmus MC within a five-year period will be invited to participate. Based on historical case numbers, we aim to include ten patients with successful recordings during this timeframe.

The surgical procedure itself will be performed entirely according to standard clinical protocols; the surgery is not part of the research intervention. Neurological functioning will be assessed pre- and postoperatively as part of routine care. Participation in the study concludes at the end of the surgical procedure. All other procedures outside the research recordings are likewise performed within standard care.

03

Conditions studied

  • Glioma
  • Glioblastoma (GBM)
  • Brain Tumor-Glioma
  • Brain Metastasis

Browse trials for

04

In context

Glioblastoma Reclassified

2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

This study's planned enrollment of 20 is below the median of 36 across 1,758 interventional studies indexed under Glioblastoma.

Browse Glioblastoma studies →

Lead sponsor

Erasmus Medical Center is the lead sponsor of 479 studies on the registry; 182 are open to participants now.

Compared within Glioblastoma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Glioma. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

The criteria were revised on the registry on Oct 5, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >18 yrs old with radiologically diagnosed brain tumor, suspect for glioma and/or .
  • Eligible for surgical resection or procedure according to standard practice.
  • Written .
  • Able to undergo intra-operative neuromonitoring.

Exclusion criteria

Exclusion Criteria:

  • History of major psychiatric disorders (e.g., schizophrenia, bipolar disorder, or severe treatment-resistant depression)
  • Previous brain tumour surgery or radiotherapy.
  • Patient has pacemaker or other implanted electrical device such as vagal nerve stimulator or other.
  • Inability to give consent.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Neuropixel probe recording

    Cortical electrophysiology using the Neuropixel probe is performed to record brain activity in the peritumoral cortex

    Device: Neuropixel probe recording

Interventions

  • DeviceNeuropixel probe recording

    Neuropixel recordings captures neuronal activity at the single-neuron level across the layers of the cortex.

    Also known as: laminar electrophysiology, cortical depth electrophysiology

07

What researchers measure

Primary outcomes

  1. Number of Participants With a Successful Intraoperative Neuropixels Probe Recording

    Feasibility is reported as the number (and percentage) of enrolled participants in whom a successful Neuropixels probe recording is obtained. A recording is counted as successful when (1) the probe is inserted into the peritumoral cortex as planned, (2) neural data are acquired during surgery with at least one isolated single neuron after spike sorting, and (3) no device-related complications occur (retained probe fragments, infection, or hemorrhage). Reasons for unsuccessful recordings are documented in the case report form.

    Time frame: From the beginning of surgery until hospital discharge

Secondary outcomes

  1. Number of Isolated Single Neurons per Participant Recorded in Peritumoral Cortex

    To assess whether intraoperative single-cell recordings are suitable for identifying prognostic biomarkers of disease progression, the number of single neurons isolated per participant is counted after spike sorting of the Neuropixels data. Only units that meet the predefined spike-sorting quality criteria are counted. Results are summarized as median (range) across participants. For each isolated neuron, the firing rate (spikes per second) and waveform characteristics are also reported descriptively.

    Time frame: From the beginning to end of surgery

08

Study locations

1 of 1 sites recruiting
09

References and documents

Publications

  • Coughlin B, Munoz W, Kfir Y, Young MJ, Meszena D, Jamali M, Caprara I, Hardstone R, Khanna A, Mustroph ML, Trautmann EM, Windolf C, Varol E, Soper DJ, Stavisky SD, Welkenhuysen M, Dutta B, Shenoy KV, Hochberg LR, Mark Richardson R, Williams ZM, Cash SS, Paulk AC. Modified Neuropixels probes for recording human neurophysiology in the operating room. Nat Protoc. 2023 Oct;18(10):2927-2953. doi: 10.1038/s41596-023-00871-2. Epub 2023 Sep 11. PubMed 37697108 ↗
  • Paulk AC, Kfir Y, Khanna AR, Mustroph ML, Trautmann EM, Soper DJ, Stavisky SD, Welkenhuysen M, Dutta B, Shenoy KV, Hochberg LR, Richardson RM, Williams ZM, Cash SS. Large-scale neural recordings with single neuron resolution using Neuropixels probes in human cortex. Nat Neurosci. 2022 Feb;25(2):252-263. doi: 10.1038/s41593-021-00997-0. Epub 2022 Jan 31. PubMed 35102333 ↗
  • Chung JE, Sellers KK, Leonard MK, Gwilliams L, Xu D, Dougherty ME, Kharazia V, Metzger SL, Welkenhuysen M, Dutta B, Chang EF. High-density single-unit human cortical recordings using the Neuropixels probe. Neuron. 2022 Aug 3;110(15):2409-2421.e3. doi: 10.1016/j.neuron.2022.05.007. Epub 2022 Jun 8. PubMed 35679860 ↗
  • Leonard MK, Gwilliams L, Sellers KK, Chung JE, Xu D, Mischler G, Mesgarani N, Welkenhuysen M, Dutta B, Chang EF. Large-scale single-neuron speech sound encoding across the depth of human cortex. Nature. 2024 Feb;626(7999):593-602. doi: 10.1038/s41586-023-06839-2. Epub 2023 Dec 13. PubMed 38093008 ↗
  • Krishna S, Choudhury A, Keough MB, Seo K, Ni L, Kakaizada S, Lee A, Aabedi A, Popova G, Lipkin B, Cao C, Nava Gonzales C, Sudharshan R, Egladyous A, Almeida N, Zhang Y, Molinaro AM, Venkatesh HS, Daniel AGS, Shamardani K, Hyer J, Chang EF, Findlay A, Phillips JJ, Nagarajan S, Raleigh DR, Brang D, Monje M, Hervey-Jumper SL. Glioblastoma remodelling of human neural circuits decreases survival. Nature. 2023 May;617(7961):599-607. doi: 10.1038/s41586-023-06036-1. Epub 2023 May 3. PubMed 37138086 ↗
  • Venkataramani V, Yang Y, Schubert MC, Reyhan E, Tetzlaff SK, Wissmann N, Botz M, Soyka SJ, Beretta CA, Pramatarov RL, Fankhauser L, Garofano L, Freudenberg A, Wagner J, Tanev DI, Ratliff M, Xie R, Kessler T, Hoffmann DC, Hai L, Dorflinger Y, Hoppe S, Yabo YA, Golebiewska A, Niclou SP, Sahm F, Lasorella A, Slowik M, Doring L, Iavarone A, Wick W, Kuner T, Winkler F. Glioblastoma hijacks neuronal mechanisms for brain invasion. Cell. 2022 Aug 4;185(16):2899-2917.e31. doi: 10.1016/j.cell.2022.06.054. Epub 2022 Jul 31. PubMed 35914528 ↗
  • Venkataramani V, Tanev DI, Strahle C, Studier-Fischer A, Fankhauser L, Kessler T, Korber C, Kardorff M, Ratliff M, Xie R, Horstmann H, Messer M, Paik SP, Knabbe J, Sahm F, Kurz FT, Acikgoz AA, Herrmannsdorfer F, Agarwal A, Bergles DE, Chalmers A, Miletic H, Turcan S, Mawrin C, Hanggi D, Liu HK, Wick W, Winkler F, Kuner T. Glutamatergic synaptic input to glioma cells drives brain tumour progression. Nature. 2019 Sep;573(7775):532-538. doi: 10.1038/s41586-019-1564-x. Epub 2019 Sep 18. PubMed 31534219 ↗

Individual participant data

Plan to share: Undecided

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Jan 2030, 48 months after the start.

Of 133 non-industry interventional studies with no phase under Glioblastoma, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 97. This study's planned 48 months is below that.

Counting every sponsor, half of 151 studies reached it within 54 months; a quarter within 36 and three quarters within 88.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 5, 2026: start Dec 2025 → Jan 2026, primary completion Jun 2029 → Jan 2030 and completion Jun 2029 → Jan 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2024
First posted
Sep 27, 2024
StartActual
Jan 1, 2026was Dec 2025
Primary completionEst.
Jan 1, 2030was Jun 2029
CompletionEst.
Jan 1, 2030was Jun 2029
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 5, 2026
Sites
1 site added — first site in Netherlands
Show site
  • Erasmus MC, Department of Neurosurgery · Rotterdam, Netherlands
Oct 5, 2026
Start date
Dec 1, 2025→Jan 1, 2026 (actual)
Oct 5, 2026
Primary completion
Jun 1, 2029→Jan 1, 2030
Oct 5, 2026
Study completion
Jun 1, 2029→Jan 1, 2030
Oct 5, 2026
Enrollment
10→20
Oct 5, 2026
Eligibility
Maximum age 90 Years→none; 3 inclusion criteria added, 2 removed; 1 exclusion criterion edited, 1 added, 2 removed
What changed in the criteria
Inclusion criteria
  • RemovedAge between 18 yrs and 90 yrs old with radiologically diagnosed GBM
  • RemovedEligible for surgery according to standard practices. If suitable and necessary according to standard practices, awake surgery is also permitted.
  • AddedAge >18 yrs old with radiologically diagnosed brain tumor, suspect for glioma and/or metastasis.
  • AddedEligible for surgical resection or biopsy procedure according to standard practice.
  • AddedAble to undergo intra-operative neuromonitoring.
Exclusion criteria
  • AddedHistory of major psychiatric disorders (e.g., schizophrenia, bipolar disorder, or severe treatment-resistant depression)
  • RemovedSevere aphasia or dysphasia
  • EditedInability to give consent because of or language barrier.
  • RemovedPsychiatric history
Oct 5, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedNumber of Participants With a Successful Intraoperative Neuropixels Probe Recordings During Glioma SurgeriesRecordingTime frame: From the beginning to end of tumor surgery → From the beginning of surgery until hospital discharge
Oct 5, 2026
Secondary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Prognostic Biomarker Identification (Unit: Number of Isolated Single Neurons with Tumor-Modulated Activity):Now Number of Isolated Single Neurons per Participant Recorded in Peritumoral CortexTime frame: From the beginning to end of surgery
Oct 5, 2026
Title
PrognosticPilot IntraOperative Biomarkers ideNtificationNeuronal Electrophysiology in Tumor rElatEd suRgery
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in Netherlands
    Show site
    • Erasmus MC, Department of Neurosurgery · Rotterdam, Netherlands
    Start date Dec 1, 2025→Jan 1, 2026 (now actual)
    Primary completion Jun 1, 2029→Jan 1, 2030
    Study completion Jun 1, 2029→Jan 1, 2030
    Enrollment 10→20
    Eligibility Maximum age 90 Years→none; 3 inclusion criteria added, 2 removed; 1 exclusion criterion edited, 1 added, 2 removed
    What changed in the criteria
    Inclusion criteria
    • RemovedAge between 18 yrs and 90 yrs old with radiologically diagnosed GBM
    • RemovedEligible for surgery according to standard practices. If suitable and necessary according to standard practices, awake surgery is also permitted.
    • AddedAge >18 yrs old with radiologically diagnosed brain tumor, suspect for glioma and/or metastasis.
    • AddedEligible for surgical resection or biopsy procedure according to standard practice.
    • AddedAble to undergo intra-operative neuromonitoring.
    Exclusion criteria
    • AddedHistory of major psychiatric disorders (e.g., schizophrenia, bipolar disorder, or severe treatment-resistant depression)
    • RemovedSevere aphasia or dysphasia
    • EditedInability to give consent because of or language barrier.
    • RemovedPsychiatric history
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedNumber of Participants With a Successful Intraoperative Neuropixels Probe Recordings During Glioma SurgeriesRecordingTime frame: From the beginning to end of tumor surgery → From the beginning of surgery until hospital discharge
    Secondary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Prognostic Biomarker Identification (Unit: Number of Isolated Single Neurons with Tumor-Modulated Activity):Now Number of Isolated Single Neurons per Participant Recorded in Peritumoral CortexTime frame: From the beginning to end of surgery
    Title PrognosticPilot IntraOperative Biomarkers ideNtificationNeuronal Electrophysiology in Tumor rElatEd suRgery
    + 6 other changes: verification date, oversight details, description, conditions, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06617208
Responsible party
Koen van der Kuil (PhD Student, Erasmus Medical Center) — Principal investigator
First posted
Sep 27, 2024
Start date
Jan 1, 2026
Primary completion
Jan 1, 2030 (estimated)
Completion
Jan 1, 2030 (estimated)
Last update
Oct 5, 2026

Study contacts

Koen van der Kuil
Contact
k.vanderkuil@erasmusmc.nl
+31641078801
Arnaud Vincent, MD PhD
Contact
a.vincent@erasmusmc.nl
Arnaud Vincent, Prof. dr.
principal investigator · Erasmus Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion